Loading icon
Press enter or spacebar to select a desired language.
Research
Press enter or spacebar to select a desired language.

PubMed COVID-19 Clinical Care

41381 - 41390 of 44979 results found

Human disturbance increases coronavirus prevalence in bats

Date
Friday, March 31, 2023 - 4:00 AM
Description
Human land modification is a known driver of animal-to-human transmission of infectious agents (zoonotic spillover). Infection prevalence in the reservoir is a key predictor of spillover, but landscape-level associations between the intensity of land

Genome-based survey of the SARS-CoV-2 BF.7 variant from Asia

Date
Friday, March 31, 2023 - 4:00 AM
Description
The SARS-CoV-2 BF.7 variant represents one of the most recent subvariant under monitoring. At the beginning of the 2023 if caused several concerns especially in Asia because of a resurge in COVID-19 cases. Here we perform a genome-based integrative

SCI Thrive: Impact of a peer-led online self-management program

Date
Friday, March 31, 2023 - 4:00 AM
Description
CONCLUSION: SCI Thrive is a highly accessible program for individuals with SCI and shows promise for improving self-efficacy. Strategies to increase engagement should be added to maximize benefits. Measurement tools may have been impacted by COVID-19

Severe systemic inflammation mimicking TAFRO syndrome following COVID-19

Date
Friday, March 31, 2023 - 4:00 AM
Description
TAFRO syndrome is a rare systemic inflammatory disease. Its pathogenesis mainly involves excessive cytokine secretion and autoimmune dysfunction. Although its etiology is unclear, some viral infections have been reported to cause it. Here, we report

Exploring research team members' and trial participants' perceptions of acceptability and implementation within one videoconference-based supportive care program for individuals affected by systemic sclerosis during COVID-19: a qualitative interview study

Date
Friday, March 31, 2023 - 4:00 AM
Description
The SPIN-CHAT Program was designed to support mental health among individuals with systemic sclerosis (SSc; commonly known as scleroderma) and at least mild anxiety symptoms at the onset of COVID-19. The program was formally evaluated in the SPIN